This approach has worked successfully for known mammalian amyloidogenic proteins including mouse PrP (an agent of transmissible spongiform encephalopathies, or prion diseases), Aβ (associated with Alzheimer’s disease), α-synuclein (associated with Parkinson’s disease), and amylin, or IAPP (associated with type II diabetes) [252]. This evidence concerns the gene IAPP and human prion disease.